MediciNova, Inc. Announces Positive Results In Study Of MN-001 In Mouse Model Of Pulmonary Fibrosis
6/12/2014 7:57:10 AM
SAN DIEGO, June 11, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive results from a study that examined the potential clinical efficacy of MN-001 (tipelukast) for the treatment of pulmonary fibrosis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by